Biocon
Biocon, Mylan tie up for generic biologic drugs
29 Jun 2009
Biocon's Kiran Mazumdar Shaw to receive Nikkei Asia Prize
11 May 2009
Shaw was nominated for her pioneering work in biotechnology in India, by establishing a business model that focuses on innovation and intellectual excellence, and her achievements as a first generation entrepreneur
Biocon’s Q4 profit plummets by 62 per cent
28 Apr 2009
Biocon eyes more acquisitions overseas
27 Feb 2008
Biocon to acquire European pharma distributor AxiCorp to enter Europe
11 Feb 2008
Biocon Ltd is acquiring a 70-per cent stake in German specialised pharmaceutical marketer and distributor AxiCorp GmbH for €30 million.
Biocon plans Rs 100 crore annual research spend
By Our Corporate Bureau | 31 Oct 2007
Drug Controller-General approves Biocon - Abraxis BioScience breast cancer drug Abraxane
By Our Corporate Bureau | 19 Oct 2007
Biocon in pact with Abraxis to market breast cancer drug Abraxane in India
By Our Corporate Bureau | 09 Aug 2007
Biocon enters into JV with Neopharma of UAE
By Our Corporate Bureau | 30 Jul 2007
Abraxis BioScience to license biosynthetic cancer drug from Biocon
By Our Corporate Bureau | 19 Jul 2007
Biocon divests enzymes for $115 million, enters into exclusive deal for bioinsulin
By Our Corporate Bureau | 18 Jul 2007
Biocon signs MoU with Australia's Deakin University
By Our Corporate Bureau | 08 Jun 2007
Biocon eyes more research outsourcing deals
By Our Corporate Bureau | 22 Mar 2007
Biocon arm to set up dedicated R&D facility for Bristol-Myers Squibb
By Our Corporate BUreau | 14 Mar 2007
Biocon to invest Rs 1,000 crore in Vizag SEZ
By Our Corporate Bureau | 17 Feb 2007
Biocon grants marketing license for cancer drug in Pakistan
By Our Corporate Bureau | 18 Jan 2007
Biocon in joint venture with Abu Dhabi-based Neopharma
By Our Corporate Bureau | 06 Jan 2007
Biocon subsidiary Clinigene completes phase-IV study on new generation insulin
By Our Corporate Bureau | 26 Dec 2006
Biocon launches cancer anti-body drug BioMab-EGFR
By Our Corporate Bureau | 18 Sep 2006
Biocon's Syngene International and Sweden's Innate Pharma to develop virulence blockers
By Our Corporate Bureau | 04 Sep 2006
Biocon Biopharmaceuticals’ new biologics facility
By Our Corporate Bureau | 17 Apr 2006
The Biocon story
By With 25 per cent of th | 07 May 2004
Biocon issue oversubscribed
By Our Corporate Bureau | 12 Mar 2004
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "Microsoft, Google challenge Delhi HC order to remove non-consensual content")
